Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.
Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.
复制标题
作者：
M. Fakih
靶向表皮生长因子受体（EGFR）已被证明在转移性结直肠癌（mCRC）的管理中具有临床获益。虽然在这种情况下使用小分子酪氨酸激酶抑制剂没有显示出任何显著的活性，并且与化疗联合使用时与胃肠道毒性增加有关，但使用EGFR靶向单克隆抗体出现了不同的情况。
Targeting the epidermal growth factor receptor (EGFR) has proven to be of clinical benefit in the management of metastatic colorectal cancer (mCRC). While the use of small-molecule tyrosine kinase inhibitors in this setting has not shown any significant activity and has been associated with increased gastrointestinal toxicity when combined with chemotherapy, a different picture has emerged with the use of EGFR-targeting monoclonal antibodies.